{
    "clinical_study": {
        "@rank": "40083", 
        "arm_group": [
            {
                "arm_group_label": "Part A", 
                "arm_group_type": "Experimental", 
                "description": "single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)"
            }, 
            {
                "arm_group_label": "Part B", 
                "arm_group_type": "Experimental", 
                "description": "single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the pharmacokinetic interactions between atorvastatin\n      and metformin single or co-administered in healthy volunteers"
        }, 
        "brief_title": "Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Willing to adhere to protocol requirements and sign a informed consent form\n\n          2. Healthy male volunteers who are in age range of 20-55 years and the weight   range is\n             not exceed \u00b120% of ideal weight. Ideal weight = [height -100]*0.9\n\n          3. Subjects with no history of any significant chronic disease\n\n          4. Judged to be in good health on the basis of their vital sign, ECG, physical exam and\n             routine laboratory data for this trial by investigators\n\n        Exclusion Criteria:\n\n          1. Subjects taking inducer or inhibitor of drug metabolism enzyme such as barbital\n             within 28days prior to study medication dosing\n\n          2. Subjects with Symptoms of acute disease within 28days prior to study medication\n             dosing\n\n          3. Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME of medicines\n\n          4. Subjects with a history of abdominal surgery within food and water limit\n\n          5. Subjects with a history of clinically significant allergies including drug allergies\n\n          6. Subjects with anaphylaxis to atorvastatin and/or metformin\n\n          7. Subjects with a history or plan iodine radiotherapy within 28 days prior to drug\n             administration\n\n          8. Subjects with a history of myopathy\n\n          9. Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase\n             deficiency or glucose-galactose malabsorption\n\n         10. Clinical laboratory test values are outside the accepted normal range\n\n               -  AST or ALT >1.25 times to normal range\n\n               -  Total bilirubin >1.5 times to normal range\n\n               -  Creatinine clearance <90 mL/min\n\n         11. Subjects with a history of drug, caffeine and alcohol abuse(caffeine > 5cups/day,\n             cigarette > 10/day, alcohol > 30g/day) or have ever drank within 7 days prior to drug\n             administration\n\n         12. Special diet known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior\n             to drug administration\n\n         13. Donated blood within 60 days prior to dosing\n\n         14. Participated in a previous clinical trial within 60 days prior to dosing\n\n         15. Subjects who have received any drugs that might confound the results of the trial\n             based on medical judgement by investigators within 10days prior to drug\n             administration\n\n         16. Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765023", 
            "org_study_id": "CJ_ATM_101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A", 
                "intervention_name": "Period I : atorvastatin, Period II : atorvastatin and metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B", 
                "intervention_name": "Period I : metformin, Period II : atorvastatin and metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Atorvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "614-735"
                }, 
                "name": "Inje University Pusan Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Fixed-sequence Study to Evaluate Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To Evaluate PK interaction of atorvastatin and metformin", 
            "safety_issue": "No", 
            "time_frame": "Throughout the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765023"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To Evaluate PK interaction of 2-OH-atorvastatin and metformin", 
            "safety_issue": "No", 
            "time_frame": "Throughout the study"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}